Barbara McDonough

Barbara McDonough

Auto-generated profile, based on publicly available information

Barbara McDonough

Division of Cardiovascular Medicine, Brigham and Women’s Hospital, Boston, MA 02115, USA

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 August 2022 in Science
Verified
Journal Article
Open access
DRDaniel Reichart
Daniel Reichart
ELEric L. Lindberg
Eric L. Lindberg
HMHenrike Maatz
Henrike Maatz
AMAntonio M. A. Miranda
Antonio M. A. Miranda
AVAnissa Viveiros
Anissa Viveiros
CSChristine Seidman
Christine Seidman
Pathogenic variants in genes that cause dilated cardiomyopathy (DCM) and arrhythmogenic cardiomyopathy (ACM) convey high risks for the development of heart failure through unknown mechanisms. Using single-nucleus RNA sequencing, we characterized the transcriptome of 880,000 nuclei from 18 control and 61 failing, nonischemic human hearts with pathogenic variants in DCM and ACM genes or idiopathic disease. We performed genotype-stratified analyses of the ventricular cell lineages and transcriptional states. The resultant DCM and ACM ventricular cell atlas demonstrated distinct right and left ventricular responses, highlighting genotype-associated pathways, intercellular interactions, and differential gene expression at single-cell resolution. Together, these data illuminate both shared and distinct cellular and molecular architectures of human heart failure and suggest candidate therapeutic targets.

23 January 2019 in Science Translational Medicine
Verified
Journal Article
Open access
PDF file
CTChristopher N. Toepfer
Christopher N. Toepfer
HWHiroko Wakimoto
Hiroko Wakimoto
AGAmanda C. Garfinkel
Amanda C. Garfinkel
BMBarbara McDonough
Barbara McDonough
DLDan Liao
Dan Liao
CSChristine Seidman
Christine Seidman
Mutations in MYBPC3 disrupt myosin states of relaxation, and manipulating myosin therapeutically abates the effects of MYBPC3 mutations.

3 March 2021 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
GRGiuliana G. Repetti
Giuliana G. Repetti
YKYuri Kim
Yuri Kim
APAlexandre C. Pereira
Alexandre C. Pereira
JIJodie Ingles
Jodie Ingles
MRMark W. Russell
Mark W. Russell
JSJ. G. Seidman
J. G. Seidman
Significance: Genetics, notably pathogenic genetic variants in sarcomere protein genes, play a major role in development of hypertrophic cardiomyopathy (HCM). However, degree of contribution from epigenetic and environmental factors in clinical presentation of HCM is currently unclear. We investigated phenotypic differences between identical twins with pathogenic sarcomere protein gene variants and demonstrated their discordant HCM presentation despite having virtually identical genomes. Our study underscores the important contribution of epigenetics and environment in disease progression in genetically diagnosed HCM patients.

18 May 2022 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
DQDaniel Quiat
Daniel Quiat
SKSeong Won Kim
Seong Won Kim
QZQi Zhang
Qi Zhang
SMSarah U. Morton
Sarah U. Morton
APAlexandre C. Pereira
Alexandre C. Pereira
JSJ. G. Seidman
J. G. Seidman
Significance: The genetic basis of isolated microtia, a congenital abnormality of the external ear, is poorly understood. Indigenous American (Amerindigenous) populations have the highest reported incidence of microtia. Here, we use whole genome sequencing to study microtia in Latin American families and identify a common microtia risk allele that is enriched among individuals with Amerindigenous ancestry. This allele is located in a regulatory region governing the expression of Roundabout 1 (ROBO1) and Roundabout 2 (ROBO2) in induced pluripotent stem cell–derived neural crest cells and is associated with a complex repeat sequence. These results identify a shared genetic basis for isolated microtia and other craniofacial abnormalities and account for, at least in part, the increased incidence of microtia in Amerindigenous populations.

31 August 2021 in Circulation: Genomic and Precision Medicine
Verified
Journal Article
Closed access
PDF file
PPParth N. Patel
Parth N. Patel
KIKaoru Ito
Kaoru Ito
JWJon A.L. Willcox
Jon A.L. Willcox
AHAlireza Haghighi
Alireza Haghighi
MJMin Young Jang
Min Young Jang
JSJ.G. Seidman
J.G. Seidman
Background: Heterozygous TTN truncating variants cause 10% to 20% of idiopathic dilated cardiomyopathy (DCM). Although variants which disrupt canonical splice signals (ie, invariant dinucleotide of the splice donor site, invariant dinucleotide of the splice acceptor site) at exon-intron junctions are readily recognized as TTN truncating variants, the effects of other nearby sequence variations on splicing and their contribution to disease is uncertain. Methods: Rare variants of unknown significance located in the splice regions of highly expressed TTN exons from 203 DCM cases, 3329 normal subjects, and clinical variant databases were identified. The effects of these variants on splicing were assessed using an in vitro splice assay. Results: Splice-altering variants of unknown significance were enriched in DCM cases over controls and present in 2% of DCM patients ( P =0.002). Application of this method to clinical variant databases demonstrated 20% of similar variants of unknown significance in TTN splice regions affect splicing. Noncanonical splice-altering variants were most frequently located at position +5 of the donor site ( P =4.4×10 7 ) and position -3 of the acceptor site ( P =0.002). SpliceAI, an emerging in silico prediction tool, had a high positive predictive value (86%–95%) but poor sensitivity (15%–50%) for the detection of splice-altering variants. Alternate exons spliced out of most TTN transcripts frequently lacked the consensus base at +5 donor and −3 acceptor positions. Conclusions: Noncanonical splice-altering variants in TTN explain 1-2% of DCM and offer a 10-20% increase in the diagnostic power of TTN sequencing in this disease. These data suggest rules that may improve efforts to detect splice-altering variants in other genes and may explain the low percent splicing observed for many alternate TTN exons.

2 January 2025 in Journal of Clinical Investigation
Verified
Journal Article
Open access
BWBryan Z. Wang
Bryan Z. Wang
MMMargaretha A.J. Morsink
Margaretha A.J. Morsink
SKSeong Won Kim
Seong Won Kim
LLLori J. Luo
Lori J. Luo
XZXiaokan Zhang
Xiaokan Zhang
Gordana Vunjak-NovakovicGordana Vunjak-Novakovic
Gordana Vunjak-Novakovic
Loss of Bcl2-associated athanogene 3 (BAG3) is associated with dilated cardiomyopathy (DCM). BAG3 regulates sarcomere protein turnover in cardiomyocytes; however, the function of BAG3 in other cardiac cell types is understudied. In this study, we used an isogenic pair of BAG3-knockout and wild-type human induced pluripotent stem cells (hiPSCs) to interrogate the role of BAG3 in hiPSC-derived cardiac fibroblasts (CFs). Analysis of cell type–specific conditional knockout engineered heart tissues revealed an essential contribution of CF BAG3 to contractility and cardiac fibrosis, recapitulating the phenotype of DCM. In BAG3 –/– CFs, we observed an increased sensitivity to TGF-β signaling and activation of a fibrogenic response when cultured at physiological stiffness (8 kPa). Mechanistically, we showed that loss of BAG3 increased transforming growth factor-β receptor 2 (TGFBR2) levels by directly binding TGFBR2 and mediating its ubiquitination and proteasomal degradation. To further validate these results, we performed single-nucleus RNA sequencing of cardiac tissue from DCM patients carrying pathogenic BAG3 variants. BAG3 pathogenic variants increased fibrotic gene expression in CFs. Together, these results extend our understanding of the roles of BAG3 in heart disease beyond the cardiomyocyte-centric view and highlight the ability of tissue-engineered hiPSC models to elucidate cell type–specific aspects of cardiac disease.